Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | WIZ | O95785 | 1/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25371673 | 1.00 | CRBN (0.61) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL30801298 | 1.00 | CRBN (0.61) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL29799690 | 1.00 | CRBN (0.61) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL30680844 | 1.00 | CRBN (0.61) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL24697760 | 1.00 | CRBN (0.61) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL29614522 | 0.94 | CRBN (0.63) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL20234982 | 0.94 | CRBN (0.63) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL21759834 | 0.93 | CRBN (0.64) | CRBNESR1CSNK1A1WIZIKZF2 | |
| SCHEMBL30646867 | 0.92 | CRBN (0.61) | CRBN | |
| SCHEMBL26658628 | 0.92 | CRBN (0.61) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539937-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | Prelude Therapeutics Incorporated (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119836416-A | KAT6 targeting compounds with ubiquitin ligase binding moiety | 普莱鲁德疗法有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2023245150-A9 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS, INCORPORATED | 2023-12-28 | — | — | US | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | KAT6A, KAT6B, KAT2A | CRBN 645/4885ESR1 1937/4885CSNK1A1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.